Stocks Health care SYRE
NASDAQ · Health careSpyre Therapeutics, Inc. (SYRE)
It posted a net loss of $178.9M. At June 30, 2026 it held $162M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 4, 2026.
What Spyre Therapeutics, Inc. does
Spyre Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SYRE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$155.2M | n/a | n/a |
| 2024 | $0 | -$208M | n/a | -$157.4M |
| 2023 | $886K | -$338.8M | $13.76 | -$99.9M |
| 2022 | $2.3M | -$83.8M | -$24.86 | -$80.2M |
| 2021 | $18.7M | -$65.8M | -$25.02 | -$54.3M |
| 2020 | $0 | -$80.9M | -$38.03 | -$80.1M |
Latest SEC filings
What Spyre Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 8, 2026
- August 25, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 4, 2026
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026
- June 26, 2026
- June 23, 2026Activist stake changed SCHEDULE 13D/A
- June 15, 2026
- June 1, 2026Other event 8-K
Questions about SYRE
What does Spyre Therapeutics, Inc. do?
Spyre Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SYRE.
Is Spyre Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $178.9M.
When did Spyre Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 4, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 8, 2026.
Similar companies
Follow SYRE
Get an email when Spyre Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow SYRE: get an email when it filesWhere the numbers come from
Financial figures are the values Spyre Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.